Obesity specialist Dr. Alexandra Sowa says long-term use makes cost the flashpoint, as insurers and employers scale back coverage and Medicare benefits face a 2027 question.
Recap by typeshit. Full story at NewsNation.
With 30% of covering employers weighing cuts, Wegovy and Zepbound users should check their plans now. Includes current self-pay prices and tips for appeals.
Endpoints News
Endpoints News reports Lilly's direct-to-patient sales model, built on Americans paying hundreds a month, is now becoming part of its plans overseas.
West Pharmaceutical shares are up about 20% since CNBC flagged the valuation in August, and the latest earnings give it reasons to expect further gains.
GEN ranks the best-selling drugs by 2025 sales, and Lilly's weight loss shot outpaced names like Merck's Keytruda on growth.
A general piece on how GLP-1 drugs like Ozempic and Wegovy reshaped weight management in the US. Light on new details.
The broker says Laurus beat 2QFY27 estimates on EBITDA and profit, with its CDMO pipeline and peptide work driving the higher forecasts.
Loading…